EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)

Journal of Thoracic Oncology

Volumn 2, Issue 5, 2007, Pages 423-429

  Cappuzzo, Federico ^a   Ligorio, Claudio ^b   Toschi, Luca ^a,b   Rossi, Elisa ^c   Trisolini, Rocco ^b   Paioli, Daniela ^b   Magrini, Elisabetta ^b   Finocchiaro, Giovanna ^b   Bartolini, Stefania ^b   Cancellieri, Alessandra ^b   Hirsch, Fred R ^d   Crino, Lucio ^e   Varella Garcia, Marileila ^d  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b BELLARIA HOSPITAL   (Italy)

^c CINECA   (Italy)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^e Ospedale Silvestrini   (Italy)

Author keywords

Akt; Chemotherapy; Epidermal growth factor receptor; HER2; Non small cell lung cancer; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; DEOXYCYTIDINE; DRUG DERIVATIVE; PROTEIN KINASE B; TAXOID; TUMOR MARKER; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER GROWTH; CONTROLLED STUDY; DNA SEQUENCE; ENZYME ACTIVATION; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHARMACOGENETICS; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; CHI SQUARE DISTRIBUTION; DISEASE COURSE; GENETICS; LUNG TUMOR; MIDDLE AGED; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SURVIVAL RATE; TAXOIDS; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 34249862665     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000268676.79872.9b     Document Type: Article

References (45)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics. CA Cancer J Clin 2001;51:15-36.
2. Non-small cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909.
3. Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
4. Kelly K, Crowley J, Bunn Jr, PA et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-3218.
5. Hanna N, Shepherd FA, Fossella FV, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2004;21:3016-3024.
6. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372.
7. Shepherd FA, Rodrigues Pereira, J, Ciuleanu T, et al. National Cancer Institute of Canada Clinical Trials Group Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
8. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Proc Am Soc Clin Oncol 2005;23:A4.
9. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246.
10. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.
11. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
12. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
13. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005;97:643-655.
14. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancer from «never-smokers» and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-13311.
15. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144.
16. Hirsch FR, Varella-Garcia M, McCoy J et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005;23:6838-6845.
17. Hirsch FR, Varella-Garcia M, Bunn PA et al. Molecular predictors of outcome with gefitinib in a Phase III placebo-controlled study in advanced non-small cell lung cancer. J Clin Oncol 2006 24:5034-5042.
18. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal-growth factor receptor positive non-small-cell lung cancer patients. J Clin Oncol 2005;23:5007-5018.
19. Cappuzzo F, Magrini E, Ceresoli GL, et al. AKT phosphorylation and gefitinib efficacy in patients with advanced Non-Small Cell Lung Cancer. J Natl Cancer Inst 2004;6:1133-1141.
20. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-1167.
21. Paz-Ares L, Sanchez JM, García-Velasco A et al. Spanish Lung Cancer Group. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2006;24:A7020.
22. Cappuzzo F, Toschi L, Trisolini R, et al. Clinical and biological effects of gefitinib in EGFR FISH positive/phospho-akt positive or never smoker non-small cell lung cancer (NSCLC): preliminary results of the ONCOBELL trial. Proc Am Soc Clin Oncol 2006;24:A7023.-
23. Inoue A, Suzuki T, Fukuhara T, et al. Prospective Phase II Study of Gefitinib for Chemotherapy-Naive Patients With Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations. J Clin Oncol 2006;24:3340-3346.
24. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777-784.
25. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794.
26. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;23:A7010.
27. Herbst RS, Prager D, Hermann R, et al. TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
28. Dixit M, Yang JL, Poirier MC, et al. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J Natl Cancer Inst 1997;89:365-373.
29. Dziadziuszko R, Holm B, Skov BG et al. Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Ann Oncol 2006 (in press).
30. Brognard J, Clark AS, Ni Y, et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61:3986-3997.
31. Cappuzzo F, Toschi L, Domenichini I, et al. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br J Cancer 2005;12:93:1334-1340.
32. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
33. Travis WD, Colby TV, Corrin B. Histological Typing of Lung and Pleural Tumors, 3rd ed. Berlin: Springer, 1999.
34. Hirsch FR, Varella-Garcia M, Bunn Jr, PA et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-3807.
35. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1985;53:457-481.
36. Lilenbaum R, Axerold R, Thomas S, et al. Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2. Proc Am Soc Clin Oncol 2006;24:A7022.
37. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909.
38. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005;23:8081-8092.
39. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346.
40. Hirsch FR, Franklin WA, McCoy J, et al. Predicting clinical benefit from EGFR TKIs: not all EGFR mutations are equal. Proc Am Soc Clin Oncol 2006;24:A7072.
41. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:3908-3914.
42. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:839-844.
43. Pritchard KI, Shepherd LE O'Malley FP et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-2111.
44. Konecny GE, Thomssen C, Luck HJ, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 2004;96:1141-1151.
45. Yang X, Fraser M, Moll UM, et al. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 2006;66:3126-3136.